Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Novel biomarkers for risk of prostate cancer: results from a case-control study.

Yang L, Gaikwad NW, Meza J, Cavalieri EL, Muti P, Trock B, Rogan EG.

Prostate. 2009 Jan 1;69(1):41-8. doi: 10.1002/pros.20850.

2.

Urinary biomarkers suggest that estrogen-DNA adducts may play a role in the aetiology of non-Hodgkin lymphoma.

Gaikwad NW, Yang L, Weisenburger DD, Vose J, Beseler C, Rogan EG, Cavalieri EL.

Biomarkers. 2009 Nov;14(7):502-12. doi: 10.3109/13547500903121715.

3.

Potential biomarker for early risk assessment of prostate cancer.

Markushin Y, Gaikwad N, Zhang H, Kapke P, Rogan EG, Cavalieri EL, Trock BJ, Pavlovich C, Jankowiak R.

Prostate. 2006 Oct 1;66(14):1565-71.

PMID:
16894534
4.
5.

The molecular etiology of breast cancer: evidence from biomarkers of risk.

Gaikwad NW, Yang L, Muti P, Meza JL, Pruthi S, Ingle JN, Rogan EG, Cavalieri EL.

Int J Cancer. 2008 May 1;122(9):1949-57.

6.
7.

Unbalanced estrogen metabolism in thyroid cancer.

Zahid M, Goldner W, Beseler CL, Rogan EG, Cavalieri EL.

Int J Cancer. 2013 Dec 1;133(11):2642-9. doi: 10.1002/ijc.28275. Epub 2013 Jun 14.

8.

Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention.

Cavalieri E, Chakravarti D, Guttenplan J, Hart E, Ingle J, Jankowiak R, Muti P, Rogan E, Russo J, Santen R, Sutter T.

Biochim Biophys Acta. 2006 Aug;1766(1):63-78. Epub 2006 Apr 19. Review.

PMID:
16675129
9.

Urine biomarkers of risk in the molecular etiology of breast cancer.

Gaikwad NW, Yang L, Pruthi S, Ingle JN, Sandhu N, Rogan EG, Cavalieri EL.

Breast Cancer (Auckl). 2009 Jan 6;3:1-8.

10.

Analysis of potential biomarkers of estrogen-initiated cancer in the urine of Syrian golden hamsters treated with 4-hydroxyestradiol.

Todorovic R, Devanesan P, Higginbotham S, Zhao J, Gross ML, Rogan EG, Cavalieri EL.

Carcinogenesis. 2001 Jun;22(6):905-11.

PMID:
11375897
11.

Unbalanced estrogen metabolism in ovarian cancer.

Zahid M, Beseler CL, Hall JB, LeVan T, Cavalieri EL, Rogan EG.

Int J Cancer. 2014 May 15;134(10):2414-23. doi: 10.1002/ijc.28565. Epub 2014 Jan 25.

12.

Inhibition of catechol-O-methyltransferase increases estrogen-DNA adduct formation.

Zahid M, Saeed M, Lu F, Gaikwad N, Rogan E, Cavalieri E.

Free Radic Biol Med. 2007 Dec 1;43(11):1534-40. Epub 2007 Aug 19.

13.

Depurinating estrogen-DNA adducts, generators of cancer initiation: their minimization leads to cancer prevention.

Cavalieri EL, Rogan EG.

Clin Transl Med. 2016 Mar;5(1):12. doi: 10.1186/s40169-016-0088-3. Epub 2016 Mar 15. Review.

14.

A unifying mechanism in the initiation of cancer and other diseases by catechol quinones.

Cavalieri EL, Rogan EG.

Ann N Y Acad Sci. 2004 Dec;1028:247-57. Review.

PMID:
15650250
15.

Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA.

Zhang Y, Gaikwad NW, Olson K, Zahid M, Cavalieri EL, Rogan EG.

Metabolism. 2007 Jul;56(7):887-94.

PMID:
17570247
16.
17.
18.

Imbalanced estrogen metabolism in the brain: possible relevance to the etiology of Parkinson's disease.

Gaikwad NW, Murman D, Beseler CL, Zahid M, Rogan EG, Cavalieri EL.

Biomarkers. 2011 Aug;16(5):434-44. doi: 10.3109/1354750X.2011.588725. Epub 2011 Jun 21.

19.

Mechanisms of estrogen carcinogenesis: The role of E2/E1-quinone metabolites suggests new approaches to preventive intervention--A review.

Yager JD.

Steroids. 2015 Jul;99(Pt A):56-60. doi: 10.1016/j.steroids.2014.08.006. Epub 2014 Aug 24. Review.

20.

Critical depurinating DNA adducts: Estrogen adducts in the etiology and prevention of cancer and dopamine adducts in the etiology and prevention of Parkinson's disease.

Cavalieri EL, Rogan EG, Zahid M.

Int J Cancer. 2017 Sep 15;141(6):1078-1090. doi: 10.1002/ijc.30728. Epub 2017 Apr 24. Review.

PMID:
28388839

Supplemental Content

Support Center